Lonza Group acquires InterHealth Nutraceuticals for $408.2m

It’s expanding its pharma and biotech markets.

Pursuing its ambition to become the world’s leading supplier to the pharmaceutical market, Lonza Group acquired the InterHealth Nutraceuticals, Inc. for a total transaction price of about $408.2 million (US$300 million).

According to Lonza, InterHealth is a leader in research, development, manufacture and marketing of proprietary, value-added nutritional ingredients for use in dietary supplements.

“We are looking forward to welcoming the highly capable team to our Lonza family. They nicely complement our offerings and will be joining us in our quest to becoming the world’s leading and most-trusted supplier to the pharmaceutical, biotech and specialty ingredients markets,” said Richard Ridinger, Lonza CEO.

Lonza’s acquisition of InterHealth is split into an upfront payment and an earn-out payment scheme. The transaction is expected to be immediately accretive to Lonza’s earnings.